In reply to comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised, crossover clinical trial’

Voriconazole ZonMw Study Group; Anette Veringa; Roger J. Brüggemann; Jan Willem C. Alffenaar

doi:10.1016/j.ijantimicag.2023.106854

In reply to comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised, crossover clinical trial’

Voriconazole ZonMw Study Group, Anette Veringa^*, Roger J. Brüggemann, Jan Willem C. Alffenaar

^*Corresponding author for this work

Microbes in Health and Disease (MHD)

Research output: Contribution to journal › Letter › Academic › peer-review

68 Downloads (Pure)

Original language	English
Article number	106854
Number of pages	2
Journal	International journal of antimicrobial agents
Volume	62
Issue number	2
DOIs	https://doi.org/10.1016/j.ijantimicag.2023.106854
Publication status	Published - Aug-2023

Access to Document

10.1016/j.ijantimicag.2023.106854

In reply to comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients- a multicenter, prospective, cluster randomised, crossover clinical trial’Final publisher's version, 226 KBLicence: Taverne

Handle.net

Persistent link

Cite this

Voriconazole ZonMw Study Group, Veringa, A., Brüggemann, R. J., & Alffenaar, J. W. C. (2023). In reply to comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised, crossover clinical trial’. International journal of antimicrobial agents, 62(2), Article 106854. https://doi.org/10.1016/j.ijantimicag.2023.106854

Voriconazole ZonMw Study Group ; Veringa, Anette ; Brüggemann, Roger J. et al. / In reply to comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients : A multicentre, prospective, cluster randomised, crossover clinical trial’. In: International journal of antimicrobial agents. 2023 ; Vol. 62, No. 2.

@article{c4a0a240034e4657a3c743c10b46250a,

title = "In reply to comment on {\textquoteleft}Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised, crossover clinical trial{\textquoteright}",

author = "{Voriconazole ZonMw Study Group} and Anette Veringa and Br{\"u}ggemann, {Roger J.} and Alffenaar, {Jan Willem C.}",

year = "2023",

month = aug,

doi = "10.1016/j.ijantimicag.2023.106854",

language = "English",

volume = "62",

journal = "International journal of antimicrobial agents",

issn = "0924-8579",

publisher = "Elsevier Bedrijfsinformatie b.v.",

number = "2",

}

Voriconazole ZonMw Study Group, Veringa, A, Brüggemann, RJ & Alffenaar, JWC 2023, 'In reply to comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised, crossover clinical trial’', International journal of antimicrobial agents, vol. 62, no. 2, 106854. https://doi.org/10.1016/j.ijantimicag.2023.106854

In reply to comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised, crossover clinical trial’. / Voriconazole ZonMw Study Group; Veringa, Anette; Brüggemann, Roger J. et al.
In: International journal of antimicrobial agents, Vol. 62, No. 2, 106854, 08.2023.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - In reply to comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients

T2 - A multicentre, prospective, cluster randomised, crossover clinical trial’

AU - Voriconazole ZonMw Study Group

AU - Veringa, Anette

AU - Brüggemann, Roger J.

AU - Alffenaar, Jan Willem C.

PY - 2023/8

Y1 - 2023/8

UR - http://www.scopus.com/inward/record.url?scp=85162205653&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2023.106854

DO - 10.1016/j.ijantimicag.2023.106854

M3 - Letter

C2 - 37209957

AN - SCOPUS:85162205653

SN - 0924-8579

VL - 62

JO - International journal of antimicrobial agents

JF - International journal of antimicrobial agents

IS - 2

M1 - 106854

ER -

Voriconazole ZonMw Study Group, Veringa A, Brüggemann RJ, Alffenaar JWC. In reply to comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised, crossover clinical trial’. International journal of antimicrobial agents. 2023 Aug;62(2):106854. doi: 10.1016/j.ijantimicag.2023.106854

In reply to comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised, crossover clinical trial’

Access to Document

Handle.net

Other files and links

Cite this